Report : Asia Pacific Anti-Infective Agents Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Type (Anti-Viral, Anti-Bacterial, Anti-Fungal, and Others), Range (Narrow Spectrum and Broad Spectrum), Route of Administration (IV, Oral, Topical, and Others), Indication (HIV, Tuberculosis, Respiratory Infection, Pneumonia, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, E-Commerce, and Others)
At 3.5% CAGR, the Asia Pacific Anti-Infective Agents Market is speculated to be worth US$ 43,478.22 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the Asia Pacific anti-infective agents market was valued at US$ 35,281.27 million in 2022 and is expected to reach US$ 43,478.22 million by 2028, registering an annual growth rate of 3.5% from 2022 to 2028. Develoment of new anti-infective agents and surging investments in R&D activities in pharmaceutical sector are the critical factors attributed to the market expansion.
Anti-infective discovery strategies are currently concentrated on two approaches: The development of antibiotic adjuvants for combined therapy with the existing antibiotics in clinical use, and the discovery of small molecules with new mechanisms of action that can disable unexplored objectives for bacterial survival. A few of the novel approaches used primarily focused on improving existing drugs. Gram-negative ESKAPE pathogens, such as Pseudomonas aeruginosa and Enterobacteriaceae, which the WHO named in 2017 as the top priority pathogens for developing novel anti-infective therapies, are known for causing multi-resistant healthcare-associated infections. Nevertheless, despite the difficulties and the expense, the creation of chemicals with novel modes of action has the potential to improve the capacity to manage microorganisms for treatments significantly.
The pharmaceutical sector invested US$ 83 billion in R&D in 2019. After accounting for inflation, that sum is roughly 10 times what the sector spent annually in the 1980s. With a peak of 59 new pharmaceuticals approved in 2018, the number of new drugs approved for sale climbed by 60% between 2010 and 2019 compared to the prior decade. R&D spending is affected by various factors. The anticipated revenue from a new drug, the anticipated development costs, and laws that affect drug supply and demand all have a role in determining how much money pharmaceutical companies invest in research and development.
The increasing investment in the pharmaceutical industry is boosting the demand for anti-infective agents. Therefore, the increasing investment in the pharmaceutical industry is expected to contribute significantly to the anti-infective agents market during the forecast period.
On the contrary, emergence of anti-infective drugs resistance and their various side effects hurdles the growth of Asia Pacific anti-infective agents market.
Based on type, the market is segmented into anti-bacterial, anti-viral, anti-fungal, and others. The anti-viral segment held the largest market share of 45.0% in 2022 with a revenue of US$ 15,874.70 million. Further, it is going to reach US$ 19,310.22 million by 2028 at decent CAGR of 3.3% during the forecasted period.
Based on range, the anti-infective agents market sphere is bifurcated into broad spectrum and narrow spectrum. The former held 69.2% market share in 2022, amassing US$ 24,418.12 million. It is projected to garner US$ 29,822.00 million by 2028 to expand at 3.2% CAGR during 2022–2028.
Based on route of administration, the market is segmented into topical, oral, IV, and others. With 48.5% share IV segment dominated the market in 2022. It accrued US$ 17,112.51 million in 2022 and is estimated to reach by US$ 20,872.99 million by 2028 at a CAGR of 3.4% during 2022-2028.
Based on indication, the market is segmented into HIV, tuberculosis, respiratory infection, pneumonia, and others. The others segment held the largest market share of 42.0% in 2022 with a revenue of US$ 14,814.18 million. Further, it is going to reach US$ 18,482.49 million by 2028 at decent CAGR of 3.8% during the forecasted period.
Based on distribution channel, the market is segmented into hospital pharmacies, specialty pharmacies, e-commerce, and others. With 48.6% share of the domain, the hospital pharmacies segment dominated the market in 2022. It accrued US$ 17,129.22 million in 2022 and is estimated to generate US$ 21,193.80 million by 2028 to grow at a CAGR of 3.6% over the forecast period.
Our country analysis states that China captured 37.6% market share in 2022. It was assessed at US$ 13,255.17 million in 2022 and is likely to hit US$ 16,736.51 million by 2028, exhibiting a CAGR of 4.0% during the forecast period.
Key players dominating the Asia Pacific anti-infective agents market are Abbott; Allergan Plc.; Astellas Pharma Inc.; Bayer AG; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline plc.; Merck & Co., Inc.; and Novartis AG among others.
Few of the recent key developments among the top market players are listed below:
- In April 2021, Abbott launched adult vaccination program for flu, typhoid, and more vaccines to safeguard people's health. The program aimed to create awareness regarding immunization in adult populations.
- In January 2021, Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO® (Ebola Zaire Vaccine, Live). ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email Id: email@example.com